bullish
Merck Alliance Provides Stability to Deal With the Outcome of High Risk Alzheimer’s R&D in FY19
255 Views03 Jul 2018 20:11
We upgrade Eisai Co Ltd (4523 JP) to “Equal-weight” after reviewing our model post FY17 (YE Mar-18) earnings, in light of the augmented peak sales...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Alzheimer's Disease and the Link with the Herpes Simplex Virus23 Oct 2018
- BAN2401 Detailed Data Presented at AAIC 2018 Validates Our Initial Concerns26 Jul 2018
- BAN2401Demonstrates Statistically Significant Clinical Data for 18 Months Study06 Jul 2018
- Eisai FY17 Earnings - First Glance17 May 2018
- Eisai Pharmaceutical - Plenty at Stake with Anti-Alzheimer R&D Programs but Lenvima Is Key20 Feb 2017
- Lenvima (Lenvatinib) – Multiple Receptor Tyrosine Kinase (RTK) Inhibitor16 Jan 2017
x